Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver

Hepatic Enzymes and Metabolic-Risk Factors Responses to Laser Acupuncture Versus Cupping Therapy in Fatty Liver

fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)

Study Overview

• Status: Recruiting
• Conditions: Fatty Liver
• Intervention / Treatment: Device: laser acupuncture; Other: wet cupping

Detailed Description

In fatty liver patients,applied cupping (with scarification) will be compared, regarding its effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ali Ismail, lecturer; Phone Number: 02 01005154209; Email: ali.mohamed@pt.cu.edu.eg
• Study Contact Backup: Name: ahmed Elfahl, Lecturer; Email: ahmed.elfahl@buc.edu.eg

Study Locations

• Egypt
  • Giza, Egypt
    • Recruiting
    • Cairo Unoversity

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• fatty liver obese patients

Exclusion Criteria:

thoracic diseases heart diseases kidney diseases

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: laser on acupuncture points; In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian	Device: laser acupuncture; In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
Active Comparator: cupping (with scarification); in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.	Other: wet cupping; in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
high density lipoprotein	it is a component of lipid profile	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
systolic blood pressure	it will be measured by sphygmomanometer	12 weeks
diastolic blood pressure	it will be measured by sphygmomanometer	12 weeks
cholesterol	it is a component of lipid profile	12 weeks
low density lipoprotein	it is a component of lipid profile	12 weeks
triglycerides	it is a component of lipid profile	12 weeks
blood glucose	fasting level of blood glucose will be measured	12 weeks
C reactive protein	high sensitivity levels C reactive protein will be measured	12 weeks
Malondialdehyde	it ts oxidative stress marker	12 weeks
aspartate transaminase	it is a hepatic enzyme that reports the functions of liver	12 weeks
alanine transaminase	it is a hepatic enzyme that reports the functions of liver	12 weeks
pulse rate	it will be measured manually	12 weeks

Collaborators and Investigators

• Sponsor: Cairo University

Study record dates

Study Major Dates

• Study Start (Actual): October 12, 2022
• Primary Completion (Anticipated): April 1, 2023
• Study Completion (Anticipated): April 1, 2023

Study Registration Dates

• First Submitted: November 14, 2022
• First Submitted That Met QC Criteria: November 18, 2022
• First Posted (Actual): November 21, 2022

Study Record Updates

• Last Update Posted (Actual): November 21, 2022
• Last Update Submitted That Met QC Criteria: November 18, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Fatty Liver
• Other Study ID Numbers: P.T.REC/012/004116

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No